Syros Pharmaceuticals (NASDAQ:SYRS) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a research report released on Tuesday. The firm issued a sell rating on the stock.

Several other research analysts also recently weighed in on SYRS. TD Cowen restated a “hold” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. Brookline Capital Management reissued a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. JMP Securities reissued a “market perform” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. Finally, HC Wainwright reiterated a “neutral” rating and issued a $1.00 target price (down from $6.00) on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. One analyst has rated the stock with a sell rating, four have issued a hold rating and one has assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $3.33.

Syros Pharmaceuticals Price Performance

Shares of Syros Pharmaceuticals stock opened at $0.14 on Tuesday. The stock has a market cap of $3.87 million, a price-to-earnings ratio of -0.05 and a beta of 1.30. The firm’s 50-day moving average is $0.20 and its two-hundred day moving average is $1.05. Syros Pharmaceuticals has a 1 year low of $0.14 and a 1 year high of $7.90.

Institutional Trading of Syros Pharmaceuticals

Large investors have recently made changes to their positions in the company. Two Sigma Securities LLC purchased a new position in Syros Pharmaceuticals in the 4th quarter worth approximately $25,000. GSA Capital Partners LLP acquired a new stake in shares of Syros Pharmaceuticals in the third quarter valued at approximately $34,000. Finally, Exome Asset Management LLC lifted its position in Syros Pharmaceuticals by 87.6% during the third quarter. Exome Asset Management LLC now owns 298,575 shares of the company’s stock worth $642,000 after buying an additional 139,400 shares in the last quarter. 91.47% of the stock is currently owned by hedge funds and other institutional investors.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.